Health anxiety and associated constructs in children and adolescents with congenital heart disease: A CHAMPS cohort study

Oliver, Amanda; Wright, Kristi D.; Kakadekar, Ashok; Pharis, Scott; Pockett, Charissa; Bradley, Timothy J.; Tomczak, Corey R.; Erlandson, Marta C

doi:10.1177/1359105318755263

Cited by 35 publications

(46 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this paper, we seek to extrapolate evidence from the HA literature to inform how health-related worries in children and young people may be managed in practice, and more specifically, how this might relate to infectious disease pandemics such as Health anxiety in children and young people HA as a disorder typically presents in early or middle adulthood (APA, 2013;Rask et al, 2016). There is some evidence to suggest that HA does occur in childhood and adolescence (Eminson et al, 1996;Oliver et al, 2018;Rask et al, 2012;Rask et al, 2016;Sirri et al, 2015;van Geelen et al, 2015;Wright and Asmundson, 2003), yet studies examining the prevalence of HA in children and young people suggest that few meet the full diagnostic criteria (Rask et al, 2016). This may be partly due to a lack of tailored, developmentally appropriate descriptions of how HA presents in children and young people (Fritz et al, 1997;Rask et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Practitioner review: health anxiety in children and young people in the context of the COVID-19 pandemic

Haig‐Ferguson

Cooper

Cartwright

et al. 2020

Behav. Cogn. Psychother.

View full text Add to dashboard Cite

Background Health-related fear is a normal and common response in the face of the global pandemic of COVID-19. Children and young people are frequently being exposed to messages about the threat to health, including from the media and authorities. Whilst for most, their anxiety will be proportionate to the threat, for some, existing preoccupation with physical symptoms and illness will become more problematic. There is a growing body of evidence that health anxiety may occur in childhood, however much of the literature is taken from research using adult samples. Aims This practitioner review aims to give an overview of the assessment and treatment of health-related worries in children and young people in the context of the COVID-19 pandemic. This review is based on the limited existing evidence in this population and the more substantial evidence base for treating health anxiety in adults. We consider the adaptations needed to ensure such interventions are developmentally appropriate.

show abstract

Section: Introductionmentioning

confidence: 99%

Practitioner review: health anxiety in children and young people in the context of the COVID-19 pandemic

Haig‐Ferguson

Cooper

Cartwright

et al. 2020

Behav. Cogn. Psychother.

View full text Add to dashboard Cite

show abstract

“…Together with the current findings and retrospective reports suggesting that adult HA is often preceded by similar symptoms in childhood and adolescence (Noyes et al, 2002), the overall evidence suggests continuity of HA across the life span. As outlined in the introduction, important findings from cross-sectional studies on children and adolescents have shown that HA is associated with a broad array of other types of psychopathology (Oliver et al, 2018;Rask et al, 2016;Rimvall et al, 2019;Sirri et al, 2015;Wright et al, 2016). Crucially, even in the adjusted analyses, there was still evidence of an independent effect of high HA at age 11 on the risk of high HA at age 16, since the findings were only partially explained by chronic somatic illness.…”

Section: Discussionmentioning

confidence: 95%

“…As outlined in the introduction, important findings from cross‐sectional studies on children and adolescents have shown that HA is associated with a broad array of other types of psychopathology (Oliver et al, 2018; Rask et al, 2016; Rimvall et al, 2019; Sirri et al, 2015; Wright et al, 2016). Crucially, even in the adjusted analyses, there was still evidence of an independent effect of high HA at age 11 on the risk of high HA at age 16, since the findings were only partially explained by chronic somatic illness.…”

Section: Discussionmentioning

confidence: 99%

Continuity of health anxiety from childhood to adolescence and associated healthcare costs: a prospective population‐based cohort study

Rimvall

Jeppesen

Skovgaard

et al. 2020

Child Psychology Psychiatry

View full text Add to dashboard Cite

Background: Severe health anxiety (HA) is characterized by excessive and impairing worry and preoccupation with health issues and can cause increased and unnecessary medical examinations. HA in childhood and adolescence is scarcely explored, hindering the potential for prevention and early intervention. Methods: HA was assessed in 1,278 children/youths at two time points at ages 11 and 16 years in a general population-based birth cohort. Registerbased data on costs related to nonhospital-based primary and secondary somatic health services were obtained over the follow-up period. The presence of functional somatic symptoms, emotional disorders and chronic somatic illness at baseline were included as covariates. Results: High HA (top 10% score) at age 11 predicted high HA at age 16 (relative risk [RR] 2.03, 95% CI: 1.26-3.31). The group with persistent HA was small (n = 17, 1.3%), resulting in broad confidence intervals. The statistical effect of HA at age 11 on HA at age 16 was heavily reduced after adjustment for sex and all covariates (RR: 1.49, 95% CI: 0.85-2.60). In the adjusted model, somatic illness at age 11 (RR: 1.91, 95% CI: 1.22-2.98) and female sex (RR: 3.33, 95% CI: 2.01-5.50) were independently associated with HA at age 16. Persistent HA was associated with approximately doubled healthcare costs compared to the group with consistently low HA. Incident HA at age 16 was associated with increased costs over follow-up. The increased costs were not explained by chronic somatic illness. Conclusions: A small subgroup of children had persistent high levels of HA from late childhood to adolescence and displayed increased healthcare costs. Female sex and chronic somatic disorders at age 11 were independent risk factors of HA at age 16. These findings provide potential means of early identification and of therapeutic levers. Further intervention development and evaluation are needed.

show abstract

“…8,12,33,39 Young children also present to cardiac neurodevelopmental programs with dysregulated sleep patterns and with separation or medical anxiety. 24,33,39,45,48,76,77 Once children reach preschool, grade retention is often considered by parents, sometimes at the recommendation of schools or providers. Grade retention recommendations are most common among children with histories of repeat or prolonged hospitalisations, and who have reduced stamina and endurance.…”

Section: Referral Patternsmentioning

confidence: 99%

“…In preschool and early elementary years, other challenges become more prominent, including learning delays or disability, 30,33,[36][37][38][39] fine and graphomotor output challenges, 1,8,[40][41][42] poor attention, 29,36,39,43 and impaired social functioning. 1,33,34,39,44 Young children with congenital heart disease are at high risk for behaviour and mood problems, 16,45,46 and may appear less socially and emotionally mature than typically developing peers. 25,[47][48][49][50] Birth through five assessment battery goals…”

Section: Introductionmentioning

confidence: 99%

Neurodevelopmental evaluation strategies for children with congenital heart disease aged birth through 5 years: recommendations from the cardiac neurodevelopmental outcome collaborative

et al. 2020

View full text Add to dashboard Cite

This paper provides specific guidelines for the neurodevelopmental evaluation of children aged birth through 5 years with complex congenital heart disease. There is wide recognition that children with congenital heart disease are at high risk for neurodevelopmental impairments that are first apparent in infancy and often persist as children mature. Impairments among children with complex congenital heart disease cross developmental domains and affect multiple functional abilities. The guidelines provided are derived from the substantial body of research generated over the past 30 years describing the characteristic developmental profiles and the long-term trajectories of children surviving with complex congenital heart conditions. The content and the timing of the guidelines are consistent with the 2012 American Heart Association and the American Academy of Pediatrics scientific statement documenting the need for ongoing developmental monitoring and assessment from infancy through adolescence. The specific guidelines offered in this article were developed by a multidisciplinary clinical research team affiliated with the Cardiac Neurodevelopmental Outcome Collaborative, a not-for-profit organisation established to determine and implement best neurodevelopmental practices for children with congenital heart disease. The guidelines are designed for use in clinical and research applications and offer an abbreviated core protocol and an extended version that expands the scope of the evaluation. The guidelines emphasise the value of early risk identification, use of evidence-based assessment instruments, consideration of family and cultural preferences, and the importance of providing multidimensional community-based services to remediate risk.

show abstract

Health anxiety and associated constructs in children and adolescents with congenital heart disease: A CHAMPS cohort study

Cited by 35 publications

References 46 publications

Practitioner review: health anxiety in children and young people in the context of the COVID-19 pandemic

Practitioner review: health anxiety in children and young people in the context of the COVID-19 pandemic

Continuity of health anxiety from childhood to adolescence and associated healthcare costs: a prospective population‐based cohort study

Neurodevelopmental evaluation strategies for children with congenital heart disease aged birth through 5 years: recommendations from the cardiac neurodevelopmental outcome collaborative

Contact Info

Product

Resources

About